GW Pharmaceuticals just released the results of its third successful Phase III clinical trial for Epidiolex (cannabidiol), a drug that can reduce the frequency of epileptic seizures. The company plans to file the drug for FDA approval early next year.

gw logoGW Pharmaceuticals is a biopharma company based in Cambridge, UK, that has built a strong portfolio of cannabinoid drugs over the years. Earlier this year, the company reported successful results for Epidiolex to reduce seizures in children with Dravet syndrome. Now, they report a second successful Phase III trial to treat Lennox-Gastaut Syndrome (LGS).

Dravet syndrome and LGS are variations of the epilepsy spectrum that start early in childhood (3-5 years) and are drug-resistant. The results of GW clinical trials show that Epidiolex can significantly reduce the number of monthly seizures by up to 42% when delivered in combination with antiepileptic drugs. And even better, these effects could be seen as early as one month after initiating the treatment.

Figure 1. Epidiolex and other Cannabinoid drugs are gaining acceptance for their effective treatment of neurological disorders

Figure 1. Epidiolex and other cannabinoid drugs are gaining acceptance for their safety and efficacy to treat neurological disorders.

The total epilepsy drug market is currently over €4B and is expected to grow to €5B by 2024. GW estimates that in 30% of the cases – which amounts to 230k people in Europe – the drugs currently on the market aren’t effective.

If its treatment receives approval, GW Pharmaceuticals could take a bite out of that sum and make life better for children… by legalizing another part of cannabis! GW’s first success was Sativex (nabiximols), which was the first ever cannabis-derived drug to be approved and is now available in 24 countries.

Hot on its heels, Epidiolex has already earned Orphan Drug and Fast Track Designation from the FDA. After these positive results were announced, GW revealed that it is getting ready to file a New Drug Application (NDA) for Epidiolex with indications for both syndromes. The NDA submission is expected during the first half of 2017.

In addition to Dravet Syndrome and LGS, GW recently started Phase III trials with Epidiolex to treat Tuberous Sclerosis Complex, a rare genetic disorder that presents epileptic seizures in 80-90% cases. And if that doesn’t work, GW also has a second candidate up its sleeve for LGS, GWP42006, currently in Phase II.

GW’s successes with cannabinoids indicate that people are getting used these therapeutics despite the potentially controversial use of otherwise illegal drugs. As marijuana is increasingly decriminalized and supported by scientific research for medical purposes, perhaps it won’t be long until its legalization is the norm!

UPDATE (Original Publication 27/09/2016): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalising marijuana.

ADVERTISEMENT
Previous post

Could Stem Cells eventually replace Animal Testing in Drug Development?

Next post

Career in Sight! Set sail for Novartis, GSK or Shire!

  • Handytrim

    Let’s not kid ourselves here. The reason why it is still illegal in many countries including the very country GW Pharmaceuticals hails from (and coincidentally continues the dishonest claim that cannabis has no medicinal qualities) is precisely why these pharma companies are all rushing to make their own patented versions of the drug. GWP have managed to largely deceive the public at large with their false claim (that was published in many of our tabloids) that their medications contain only elements of cannabis when in actual fact the CEO of the company is on record stating that they contain ALL elements present in the plant.

    The most controversial point in this whole disgraceful episode in our history is our medical community’s seemingly ignorant silence towards the proven benefits and the parroting of the now widely debunked Reefer Madness propaganda that saw cannabis removed as a legitimate medicine largely thanks to one racist DEA agent’s crusade that kept him and his department in the job (and the prisons filled) and the corrupt nature of the League of Nations who lumped cannabis in the same category as opium at the request of the Egyptian cotton industry.

    At least we appear to be moving away from the awful patented synthasised cannabis compounds that have had very poor (often many times more harmful) results compared to the natural unpatentable equivilant.

    The alcohol and pharmacuetical industries will continue to fight tooth and nail to keep cannabis banned. Thankfully they are losing that fight in America, but in the UK they are still very much control our policy making.